Press Releases

Sign Up For Updates
Date Description View
12/20/17

Denali Therapeutics Announces Advancement And Expansion Of Its LRRK2 Inhibitor Clinical Program For Parkinson’s Disease

12/12/17

Denali Therapeutics Announces Closing Of Initial Public Offering, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares

12/07/17

Denali Therapeutics Announces Pricing Of Initial Public Offering

08/25/16

Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations And $130M Series B

09/08/15

Denali Therapeutics Appoints Steve E. Krognes As Chief Financial Officer

07/22/15

Denali Therapeutics Appoints Carole Ho, M.D., As Chief Medical Officer And Head Of Development

05/14/15

Denali Therapeutics Launches With Initial Investment To Discover And Develop Treatments For Neurodegenerative Diseases


Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox

Required fields denoted by an asterisk (*).

Investors & Media Relations